Immune Pharmaceuticals Company Profile (NASDAQ:IMNP)

About Immune Pharmaceuticals (NASDAQ:IMNP)

Immune Pharmaceuticals logoImmune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $14.67 million
  • Outstanding Shares: 13,586,000
Average Prices:
  • 50 Day Moving Avg: $1.38
  • 200 Day Moving Avg: $1.82
  • 52 Week Range: $1.01 - $7.15
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.01) per share
  • Price / Book: -107.00
Profitability:
  • EBIDTA: ($12,480,000.00)
  • Return on Equity: -552.76%
  • Return on Assets: -107.04%
Debt:
  • Debt-to-Equity Ratio: -16.69%
  • Current Ratio: 0.02%
  • Quick Ratio: 0.02%
Misc:
  • Average Volume: 617,316 shs.
  • Beta: 2.1
  • Short Ratio: 6.84
 

Frequently Asked Questions for Immune Pharmaceuticals (NASDAQ:IMNP)

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) posted its quarterly earnings results on Monday, August, 15th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). View Immune Pharmaceuticals' Earnings History.

When will Immune Pharmaceuticals make its next earnings announcement?

Immune Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November, 17th 2017. View Earnings Estimates for Immune Pharmaceuticals.

Where is Immune Pharmaceuticals' stock going? Where will Immune Pharmaceuticals' stock price be in 2017?

1 analysts have issued 1-year price objectives for Immune Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Immune Pharmaceuticals' stock price to reach $3.00 in the next year. View Analyst Ratings for Immune Pharmaceuticals.

Who are some of Immune Pharmaceuticals' key competitors?

Who are Immune Pharmaceuticals' key executives?

Immune Pharmaceuticals' management team includes the folowing people:

  • Elliot M. Maza J.D., CPA, Interim Chief Executive Officer, Director
  • John Militello CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller
  • Anthony Fiorino M.D. Ph.D., Chief Operating Officer, Chief Medical Officer
  • Cameron Durrant M.D., Lead Independent Director
  • Daniel G. Teper Pharm.D., Director
  • John A Neczesny, Independent Director
  • Jeffrey Paley M.D., Independent Director

Who owns Immune Pharmaceuticals stock?

Immune Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.28%) and Susquehanna International Group LLP (0.69%). Company insiders that own Immune Pharmaceuticals stock include Daniel Gedeon Teper, Daniel Kazado and Monica E Luchi. View Institutional Ownership Trends for Immune Pharmaceuticals.

Who sold Immune Pharmaceuticals stock? Who is selling Immune Pharmaceuticals stock?

Immune Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Immune Pharmaceuticals.

Who bought Immune Pharmaceuticals stock? Who is buying Immune Pharmaceuticals stock?

Immune Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. Company insiders that have bought Immune Pharmaceuticals stock in the last two years include Daniel Gedeon Teper, Daniel Kazado and Monica E Luchi. View Insider Buying and Selling for Immune Pharmaceuticals.

How do I buy Immune Pharmaceuticals stock?

Shares of Immune Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immune Pharmaceuticals' stock price today?

One share of Immune Pharmaceuticals stock can currently be purchased for approximately $1.07.


MarketBeat Community Rating for Immune Pharmaceuticals (NASDAQ IMNP)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Immune Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immune Pharmaceuticals (NASDAQ:IMNP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.00 (180.37% upside)

Analysts' Ratings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2016FBR & CoReiterated RatingOutperform$3.00N/AView Rating Details
5/16/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
4/4/2016Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Immune Pharmaceuticals (NASDAQ:IMNP)
Earnings by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Earnings History by Quarter for Immune Pharmaceuticals (NASDAQ IMNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2017        
8/15/2016Q2($0.13)($0.13)ViewN/AView Earnings Details
5/16/2016Q116($0.15)($0.17)ViewN/AView Earnings Details
3/30/2016Q4($0.16)($0.27)ViewN/AView Earnings Details
11/12/2015Q315($0.18)($0.33)$15.00 millionViewListenView Earnings Details
8/17/2015Q215($0.19)($0.12)ViewN/AView Earnings Details
5/18/2015Q1($0.20)($0.15)ViewN/AView Earnings Details
4/15/2015Q4 2014($0.37)($0.34)ViewN/AView Earnings Details
8/14/2014Q2 2014($0.21)($0.27)ViewN/AView Earnings Details
5/21/2014Q1 2014($0.15)($0.35)ViewN/AView Earnings Details
4/10/2014Q4 2013($0.15)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Pharmaceuticals (NASDAQ:IMNP)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Immune Pharmaceuticals (NASDAQ:IMNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Ownership Percentage: 6.74%
Institutional Ownership Percentage: 3.39%
Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Insider Trades by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Daniel KazadoDirectorBuy76,503$0.19$14,535.57View SEC Filing  
12/16/2016Daniel KazadoDirectorBuy161,377$0.19$30,661.63View SEC Filing  
8/4/2016Daniel Gedeon TeperCEOBuy937,500$0.38$356,250.00View SEC Filing  
8/4/2016Daniel KazadoDirectorBuy666,667$0.45$300,000.15View SEC Filing  
8/4/2016Monica E LuchiCMOBuy777,778$0.45$350,000.10View SEC Filing  
1/26/2016Daniel Gedeon TeperCEOBuy42,000$0.59$24,780.00View SEC Filing  
1/19/2016Daniel Gedeon TeperCEOBuy44,200$0.57$25,194.00View SEC Filing  
1/12/2016Daniel Gedeon TeperCEOBuy39,400$0.62$24,428.00View SEC Filing  
1/5/2016Daniel Gedeon TeperCEOBuy62,000$0.81$50,220.00View SEC Filing  
12/7/2015Daniel Gedeon TeperCEOBuy65,400$0.76$49,704.00View SEC Filing  
12/7/2015Daniel KazadoDirectorBuy150,000$0.78$117,000.00View SEC Filing  
10/26/2015Daniel Gedeon TeperCEOBuy18,400$1.36$25,024.00View SEC Filing  
10/19/2015Daniel Gedeon TeperCEOBuy18,600$1.34$24,924.00View SEC Filing  
10/12/2015Daniel Gedeon TeperCEOBuy19,000$1.30$24,700.00View SEC Filing  
10/5/2015Daniel Gedeon TeperCEOBuy40,700$1.23$50,061.00View SEC Filing  
9/14/2015Rene Pierre AzriaDirectorBuy50,000$1.48$74,000.00View SEC Filing  
9/1/2015Daniel Gedeon TeperCEOBuy7,569$1.29$9,764.01View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Immune Pharmaceuticals (NASDAQ:IMNP)
Latest Headlines for Immune Pharmaceuticals (NASDAQ:IMNP)
Source:
DateHeadline
streetinsider.com logoImmune Pharma (IMNP) Receives NASDAQ Letter
www.streetinsider.com - August 31 at 7:53 PM
businesswire.com logoImmune Pharmaceuticals Provides R&D and Business Update and ... - Business Wire (press release)
www.businesswire.com - August 30 at 2:08 AM
streetinsider.com logoImmune Pharma (IMNP) Receives NASDAQ Letter - StreetInsider.com
www.streetinsider.com - August 30 at 2:08 AM
finance.yahoo.com logoImmune Pharmaceuticals Receives NASDAQ Letter
finance.yahoo.com - August 30 at 2:08 AM
globenewswire.com logoInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
globenewswire.com - August 24 at 7:57 AM
streetinsider.com logoImmune Pharma (IMNP) Appoints Tony Fiorino, MD, PhD as CMO and COO - StreetInsider.com
www.streetinsider.com - August 15 at 3:25 AM
finance.yahoo.com logoImmune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer
finance.yahoo.com - August 14 at 10:23 PM
businesswire.com logoCYTOVIA Inc, IMMUNE Pharma's Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic ... - Business Wire (press release)
www.businesswire.com - August 9 at 8:08 PM
finance.yahoo.com logoCYTOVIA Inc, IMMUNE Pharma’s Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent
finance.yahoo.com - August 9 at 8:08 PM
businesswire.com logoCYTOVIA Inc., IMMUNE Pharma's Oncology Subsidiary, Announces ... - Business Wire (press release)
www.businesswire.com - August 8 at 7:33 PM
businesswire.com logoCYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting ...
www.businesswire.com - August 7 at 7:19 PM
finance.yahoo.com logoCYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML)
finance.yahoo.com - August 7 at 7:19 PM
americanbankingnews.com logoContrasting Theravance Biopharma (TBPHV) and Immune Pharmaceuticals (IMNP)
www.americanbankingnews.com - August 1 at 10:26 PM
americanbankingnews.com logoSCYNEXIS (SCYX) versus Immune Pharmaceuticals (IMNP) Financial Analysis
www.americanbankingnews.com - August 1 at 8:04 AM
americanbankingnews.com logoCambrex Corporation (CBM) vs. Immune Pharmaceuticals (NASDAQ:IMNP) Head-To-Head Review
www.americanbankingnews.com - July 24 at 10:18 PM
reuters.com logoBRIEF-Immune Pharmaceuticals provides update on plan to spin-off Cytovia - Reuters
www.reuters.com - July 19 at 8:56 PM
streetinsider.com logoImmune Pharma (IMNP) Provides Update on Spin-off of Cytovia - StreetInsider.com
www.streetinsider.com - July 19 at 8:56 PM
finance.yahoo.com logoImmune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company
finance.yahoo.com - July 19 at 8:56 PM
businesswire.com logoIMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting ... - Business Wire (press release)
www.businesswire.com - July 15 at 2:13 AM
businesswire.com logoIMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other ...
www.businesswire.com - July 14 at 3:49 AM
finance.yahoo.com logoIMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1
finance.yahoo.com - July 14 at 3:49 AM
streetinsider.com logoImmune Pharma (IMNP) Subsidiary Enters into Definitive Agreement with Pint Pharma for Licensing and ... - StreetInsider.com
www.streetinsider.com - July 13 at 3:10 AM
businesswire.com logoCytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene ® in Latin ...
www.businesswire.com - July 11 at 11:50 PM
streetinsider.com logoImmune Pharma (IMNP) Subsidiary Enters into Definitive Agreement with Pint Pharma for Licensing and Commercialization of Ceplene in Latin America
www.streetinsider.com - July 11 at 11:50 PM
finance.yahoo.com logoCytovia Inc, Immune Pharmaceuticals’ Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America
finance.yahoo.com - July 11 at 11:50 PM
finance.yahoo.com logoIMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal
finance.yahoo.com - July 6 at 5:52 AM
streetinsider.com logoImmune Pharma (IMNP) Subsidiary, Cytovia, Announces Ceplene Licensing & Commercialization Agreement for Latin America
www.streetinsider.com - July 2 at 12:19 AM
streetinsider.com logoImmune Pharma (IMNP) Subsidiary, Cytovia, Announces Ceplene Licensing & Commercialization Agreement for Latin ... - StreetInsider.com
www.streetinsider.com - June 30 at 7:57 PM
finance.yahoo.com logoImmune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America
finance.yahoo.com - June 30 at 12:10 AM
prnewswire.com logoImmune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic ... - PR Newswire (press release)
www.prnewswire.com - June 20 at 11:59 PM
finance.yahoo.com logoImmune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML)
finance.yahoo.com - June 20 at 6:48 PM
finance.yahoo.com logoImmune Receives NASDAQ Compliance Letter
finance.yahoo.com - June 19 at 12:22 PM
streetinsider.com logoImmune Pharma (IMNP) to Regain Worldwide Rights for Ceplene - StreetInsider.com
www.streetinsider.com - June 17 at 6:26 PM
streetinsider.com logoImmune Pharma (IMNP) to Regain Worldwide Rights for Ceplene
www.streetinsider.com - June 16 at 5:07 AM
finance.yahoo.com logoImmune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene
finance.yahoo.com - June 16 at 5:07 AM
americanbankingnews.com logoImmune Pharmaceuticals (IMNP) vs. Bristol-Myers Squibb Company (BMY) Critical Survey
www.americanbankingnews.com - June 15 at 2:08 PM
prnewswire.com logoResearch Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera ... - PR Newswire (press release)
www.prnewswire.com - June 2 at 8:08 AM
streetinsider.com logoImmune Pharma (IMNP) Regains Compliance with Min. Bid Price Rule Citing Letter from Nasdaq
www.streetinsider.com - May 27 at 4:43 AM
finance.yahoo.com logoImmune Receives Nasdaq Letters
finance.yahoo.com - May 26 at 6:38 PM
americanbankingnews.com logoImmune Pharmaceuticals Inc (IMNP) Short Interest Up 35.8% in April
www.americanbankingnews.com - May 13 at 7:12 AM
americanbankingnews.com logoShort Interest in Immune Pharmaceuticals Inc (IMNP) Expands By 6.4%
www.americanbankingnews.com - May 9 at 7:12 AM
streetinsider.com logoImmune Pharma (IMNP) Announces Private Placement of up to $3.4 ... - StreetInsider.com
www.streetinsider.com - May 4 at 6:03 PM
finance.yahoo.com logoImmune Pharmaceuticals Announces Private Placement of up to $3.4 Million
finance.yahoo.com - May 4 at 6:03 PM
streetinsider.com logoImmune Pharma (IMNP) Announces Corporate Restructuring, CEO to Resign
www.streetinsider.com - April 24 at 5:33 PM
finance.yahoo.com logoImmune Receives Nasdaq Letter
finance.yahoo.com - April 24 at 9:31 AM
finance.yahoo.com logoImmune Pharmaceuticals Announces Corporate Restructuring
finance.yahoo.com - April 24 at 9:30 AM
finance.yahoo.com logoImmune Pharma shares tumble 9% premarket as it unveils restructuring
finance.yahoo.com - April 24 at 9:30 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Affect Immune Pharmaceuticals (IMNP) Stock Price
www.americanbankingnews.com - April 22 at 11:59 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Aurinia ... - Yahoo Finance
finance.yahoo.com - April 22 at 8:10 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals
finance.yahoo.com - April 21 at 10:43 AM

Social

Chart

Immune Pharmaceuticals (IMNP) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff